Products - Chronic kidney disease | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 49 products

Date | Title

Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Chronic kidney disease: assessment and management (NG203)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
24 November 2021
Published:
25 August 2021
Chronic kidney disease in adults (QS5)
Product type:
Quality standard
Last updated:
27 July 2017
Published:
30 March 2011
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2007
Dapagliflozin for treating chronic kidney disease (TA775)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 March 2022
Dapagliflozin for treating chronic kidney disease [ID6411]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Difelikefalin for treating pruritus in people having haemodialysis (TA890)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 May 2023
Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
5 August 2020
Empagliflozin for treating chronic kidney disease (TA942)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2023
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 March 2023
Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
11 August 2020
Healthy.io test for home testing of urine albumin to creatinine ratio
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 July 2022
Immunosuppressive therapy for kidney transplant in adults (TA481)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Iptacopan for treating complement 3 glomerulopathy [ID6283]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 January 2026
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Laparoscopic insertion of peritoneal dialysis catheter (IPG208)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 February 2007
Laparoscopic live donor simple nephrectomy (IPG57)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 May 2004
Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 August 2005
Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 October 2021
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 January 2009
Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
21 June 2017
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Obinutuzumab for treating lupus nephritis ID6420
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access (IPG710)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 October 2021
Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
13 November 2019
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
13 December 2022
Renal replacement therapy and conservative management (NG107)
Product type:
Guidance
Programme:
NICE guideline
Published:
3 October 2018
Renal replacement therapy services for adults (QS72)
Product type:
Quality standard
Last updated:
3 October 2018
Published:
28 November 2014
Robot-assisted kidney transplant (IPG609)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 April 2018
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Sibeprenlimab for treating IgA nephropathy [TSID12111]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Single-port laparoscopic nephrectomy (IPG414)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 November 2011
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
24 January 2022
Published:
4 September 2019
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sparsentan for treating primary IgA nephropathy [ID6308]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
27 June 2025
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2023
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 December 2025
The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
19 November 2014
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2015
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2025
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 May 2023